Floatz logo

Bcma/Gprc5D Car-T Cells

Sarcoma, Ewing

Essen BiotechCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Sarcoma, Ewing cohort.

Asset / SponsorPhaseRating
HSP90-TARGETED SN-38 CONJUGATE PEN-866
National Cancer Institute (NCI)
Phase 1/2CCC
cd146/her2 car-t cells
Essen Biotech
Phase 1/2CCC
Thalidomide
Washington University School of Medicine
Phase 1CC

Same molecule, other indications

Bcma/Gprc5D Car-T Cells is also rated in:

Sarcoma, KaposiDormant
CCC
Indicative ·
48 / 100
View asset →
Sarcoma,Soft TissueDormant
CCC
Indicative ·
48 / 100
View asset →
Sarcoma, SynovialDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →